Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Infections and IBD.

Peter M Irving1, Peter R Gibson

  • 1Department of Gastroenterology, Box Hill Hospital, Box Hill, Victoria, Australia.

Nature Clinical Practice. Gastroenterology & Hepatology
|January 5, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Letter: Lost in Translation-Replicating a Modifying FODMAP Diet in Patients With IBS.

Alimentary pharmacology & therapeutics·2026
Same author

Critical Review: The Past, Present, and Future of Small Intestinal Bacterial Overgrowth (SIBO).

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

Real-Time Evaluation of Gastrointestinal pH and Transit Time in Patients With Essential Hypertension.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Development and Evaluation of a Sham Diet Intended as a Placebo-Control Diet for Food-Based Interventional Trials in Ulcerative Colitis.

Journal of the Academy of Nutrition and Dietetics·2026
Same author

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Inflammatory bowel diseases·2026
Same author

A Qualitative Template Analysis to Understand Patient and Practitioner Perspectives on a Psychological Intervention for Fatigue in Inflammatory Bowel Disease.

JGH open : an open access journal of gastroenterology and hepatology·2026
Same journal

Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers.

Nature clinical practice. Gastroenterology & hepatology·2009
Same journal

A perfect storm.

Nature clinical practice. Gastroenterology & hepatology·2009
Same journal

Gastric electric stimulation is a viable option in gastroparesis treatment.

Nature clinical practice. Gastroenterology & hepatology·2009
Same journal

Misconception of treatment for liver disease unique to pregnancy.

Nature clinical practice. Gastroenterology & hepatology·2009
Same journal

Probiotic prophylaxis in acute pancreatitis: prudence required.

Nature clinical practice. Gastroenterology & hepatology·2009
Same journal

Duration of treatment with albendazole for hepatic toxocariasis.

Nature clinical practice. Gastroenterology & hepatology·2009
See all related articles

Infections can trigger inflammatory bowel disease (IBD) onset and relapse. Managing IBD involves awareness of infection risks from medications and vaccinations, with new parasite-based therapies emerging.

Area of Science:

  • Gastroenterology
  • Immunology
  • Infectious Diseases

Background:

  • The interplay between infections and inflammatory bowel disease (IBD) has been recognized since the initial descriptions of Crohn's disease and ulcerative colitis.
  • Infectious agents play a multifaceted role in both the development (etiopathogenesis) and progression of IBD.

Purpose of the Study:

  • To review the complex relationship between infections and IBD.
  • To highlight how infections can initiate IBD onset and relapses.
  • To discuss the increased susceptibility to infections in IBD patients and the impact of IBD treatments on infectious risks.

Main Methods:

  • Literature review and synthesis of existing research on infection and IBD.
  • Analysis of the impact of IBD disease processes on infection risk.

Related Experiment Videos

  • Evaluation of infectious risks associated with IBD pharmacotherapies, including immunomodulators and combination therapies.
  • Consideration of vaccination status in IBD patients.

    • Main Results:

    • Infections are clearly implicated in initiating and causing relapses of IBD.
    • IBD pathogenesis increases patient susceptibility to specific infections.
    • IBD treatments, particularly combined immunomodulatory agents, elevate the risk of infectious complications.
    • Suboptimal vaccination coverage and response may exacerbate infection risks in IBD patients.

    Conclusions:

    • Physicians must be vigilant regarding infectious risks in IBD patients and implement preventative strategies.
    • Combined immunomodulatory therapies appear to pose the highest infectious risk.
    • Novel therapeutic approaches, including the use of parasitic agents for IBD, represent a new dimension in understanding infection-IBD interactions.